NCT00051181
Completed
Phase 3
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Glaucoma, Angle-Closure
- Sponsor
- Alcon Research
- Locations
- 2
- Status
- Completed
- Last Updated
- 17 years ago
Overview
Brief Summary
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 4
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular HypertensionGlaucomaNCT00763061Alcon Research111
Completed
Phase 4
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension GlaucomaNormal Tension GlaucomaOcular HypertensionNCT01995136Alcon Research32
Completed
Phase 3
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)Glaucoma, Open-AngleOcular HypertensionNCT00051142Alcon Research
Completed
Phase 4
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on TimololGlaucomaNCT01336569Alcon Research50
Completed
Phase 3
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma PatientsPediatric GlaucomaElevated IOP in Pediatric PatientsOcular Hypertension in Pediatric PatientsNCT01652664Alcon Research184